Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson's Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Introduction. Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mawatari, Shiro, Ohara, Shinji, Taniwaki, Yoshihide, Tsuboi, Yoshio, Maruyama, Toru, Fujino, Takehiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049862/
https://www.ncbi.nlm.nih.gov/pubmed/32148751
http://dx.doi.org/10.1155/2020/2671070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049862/
https://www.ncbi.nlm.nih.gov/pubmed/32148751
http://dx.doi.org/10.1155/2020/2671070

Ejemplares similares